Lung Cancer: 854 Real Stories

854 stories match lung cancer. 428 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed Central
OutcomeIn Memory
Roy, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Stage II KRAS Lung Adenocarcinoma: Roy's Survivor Story

Patient Info: Roy, Male, 50s | Stage II

Biomarkers: KRAS

As of May 2026, Roy described being cancer-free/in remission, back to flying professionally, and strong enough to complete his 5th marathon at the Boston Marathon.

The Patient Story
OutcomeCancer-Free / NED
Jake, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient Story
OutcomeLiving With Cancer
Kartik, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Kartik's Patient Story

Patient Info: Kartik, Male, Under 40 | Stage IV

Biomarkers: EML4/ALK mutation

Kartik was diagnosed with Stage IV ALK-rearranged lung cancer at age 28, continued working for several years through a targeted clinical trial, and died in 2015 at age 34.

GO2 Foundation
OutcomeIn Memory
Susie, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage III Non-Small Cell Lung Cancer: Susie's Survivor Story

Patient Info: Susie, Female | Stage III

As of May 2026, Susie described completed surgery, chemotherapy, and radiotherapy for Stage III non-small cell lung cancer and was advocating for smoke-free legislation; no NED status was stated.

Cancer Research UK
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Stage IIIA small-cell lung cancer with anti-NMDAR encephalitis: initial complete response, recurrence, and death

Patient Info: Anonymized, Male, 60s

Biomarkers: CSF positive for anti-NMDAR antibodies; no tumor molecular biomarkers reported

The patient initially had rapid neurologic recovery and complete radiologic response after carboplatin, etoposide, and atezolizumab, but the primary lung lesion recurred 7 months later and he died 21 months after disease onset.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA EGFR-mutated lung adenocarcinoma: stable disease on first-line osimertinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; baseline EGFR exon 20 T790M mutation; ALK IHC negative; PD-L1 TPS 30%; TTF-1-positive

Metastatic Site: pleura; malignant pleural-pericardial adhesions

As of April 2026, she had stable disease for more than 9 months on first-line osimertinib, with no progressive disease, no recurrent pleural effusion, ECOG improvement from 2 to 0, and no treatment-related adverse events.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV squamous NSCLC: durable pembrolizumab response followed by invasive aspergillosis, marrow failure, and death

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 20%

Metastatic Site: bilateral lungs

After durable partial response to pembrolizumab-based therapy, he developed severe pulmonary infection, invasive pulmonary aspergillosis, progressive AA-like bone marrow failure with severe cytopenias, declined further treatment, and died at home in early 2025.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Inflammatory Breast CancerLung Cancer

Pulmonary nodules mimicking lung cancer in MPO-ANCA vasculitis with kidney injury

Patient Info: Anonymized, Female, Under 40

Biomarkers: Initial vasculitis/kidney markers: MPO-ANCA and anti-GBM positive, high creatinine/proteinuria, anemia.

As of November 20, 2023, kidney function had improved, dialysis was stopped, ANCA/GBM antibodies were negative, pulmonary nodules were much smaller, and she was maintained on azathioprine 100 mg daily.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage IV squamous lung cancer with steroid-refractory immune-related gastritis after pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Gastric biopsy during immune gastritis showed CD8-positive lymphocyte inflammation, no cancer

After about 2 years of carboplatin, pemetrexed, and pembrolizumab, lung cancer treatment was stopped because of tumor growth; the later immune-related gastritis improved after escalation to infliximab, while the cancer course remained a setback/progression story.

PubMed Central
OutcomeSetback / Progression
Michelle, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II Lung Cancer: Michelle's Patient Story

Patient Info: Michelle, Female | Stage II

Receiving ongoing adjuvant treatment after lung cancer first thought to be Stage I was upgraded to Stage IIB because 3 of 18 lymph nodes were positive.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage IV lung cancer response followed by immune-related lung inflammation

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Metastatic Site: pleura

After the lung inflammation improved, he did not resume tumor-directed chemotherapy, immunotherapy, or radiation and remained generally well.

PubMed Central
OutcomeLiving With Cancer
Kelsey, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient Story
OutcomeResponding Well
Daniel, who was diagnosed with Stage II Non-Small Cell Lung CancerLung Cancer

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Patient Story

Patient Info: Daniel West, Male, 50s | Stage II

Biomarkers: EGFR positive

As of April 2026, Daniel had shown no evidence of active disease for more than 2 years, while remaining on daily osimertinib through June 2026 and receiving checkups and scans every 3 months for stable monitored lung nodules.

MD Anderson
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Synchronous Stage IA lung adenocarcinoma and grade 4 glioblastoma: lung nodule regressed during brain-cancer therapy

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Lung molecular biomarkers not reported; glioblastoma biomarker details not summarized in library fields

The Stage IA lung adenocarcinoma was monitored without lung-directed therapy and decreased from 18 mm to 9 mm while CNS-directed glioblastoma treatment continued; she remained alive with no lung cancer progression.

PubMed Central
OutcomeCare Ongoing